Summary & Overview
HCPCS A2027: Matriderm Dermal Substitute, Per Square Centimeter
HCPCS Level II code A2027 designates Matriderm, a dermal substitute billed per square centimeter as an add-on supply in addition to a primary procedure. This code captures use of an acellular dermal matrix in reconstructive and wound-healing surgical care and is relevant for accurate supply reporting and clinical documentation nationwide. Payors commonly evaluated in relation to this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for Matriderm, common billing considerations for an add-on per-area supply code, and the typical sites of service where the product is used. The publication outlines standard benchmarks and payer coverage themes, highlights coding and billing flags to watch for when appending an add-on per-square-centimeter supply, and summarizes any notable policy updates affecting reimbursement and documentation practices. Where input data is incomplete, the text indicates that information is not available in the input rather than supplying unverified details. This resource is intended to support billing, clinical documentation, and revenue cycle decisions at a national level by clarifying the purpose and application of HCPCS Level II code A2027 for Matriderm.
Billing Code Overview
HCPCS Level II code A2027 describes Matriderm, billed per square centimeter as an add-on supply code to be listed separately in addition to the primary procedure. The service type is a biologic dermal substitute used in soft tissue and wound reconstruction. The typical site of service is outpatient surgical settings, hospital outpatient departments, and specialized wound care clinics where tissue grafting or reconstructive procedures are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with a full-thickness skin defect from trauma or surgical excision (for example, removal of an infected tissue or tumor) is scheduled for operative wound reconstruction. During the procedure the surgeon debrides nonviable tissue and prepares the wound bed. A biologic dermal matrix, A2027 (Matriderm) is applied to the wound surface as an adjunct to facilitate dermal regeneration and improve integration of a subsequent split-thickness skin graft. Typical workflow includes preoperative evaluation in the operating room, intraoperative wound bed preparation, sizing and application of the Matriderm product by the surgical team, fixation with sutures or staples, and placement of a split-thickness skin graft and appropriate dressing. Typical site of service is an inpatient or outpatient surgical suite or ambulatory surgery center. Typical patient scenario: a 56-year-old patient with a chronic lower-extremity ulcer after trauma with exposed subcutaneous tissue, requiring debridement and placement of a dermal regenerative matrix followed by skin grafting under procedural anesthesia; insurance coverage may involve Medicare, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, or a commercial carrier with prior authorization requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Denotes standard professional service | Rarely used; indicates no unusual circumstances when required by payer format |